Diseases treated with immunoglobulin therapy, such as myasthenia gravis and idiopathic thrombocytopenic purpura
Conditions
Interventions
None listed
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are scheduled to receive immunoglobulin therapy for diseases such as myasthenia gravis and idiopathic thrombocytopenic purpura. 2) Patients who have received a full explanation of and fully understood the details of participating in this study and have voluntarily provided written consent.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria are ineligible to participate in this study. 1) Patients who have received immunoglobulin therapy within the past six months. 2) Patients who tested positive for islet-associated autoantibodies (GAD antibody, IA-2 antibody, insulin antibody, ZnT8 antibody) before starting immunoglobulin therapy. 3) Patients who may discontinue outpatient treatment at our hospital due to reasons such as transferring to another hospital or moving within three months of obtaining consent. 4) Patients who are deemed unsuitable for the safe implementation of this study by the principal investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients who seroconvert to positive for one or more islet-associated autoantibodies (GAD antibody, IA-2 antibody, insulin antibody, and ZnT8 antibody) after immunoglobulin therapy (IVIg). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The time it takes for islet-associated autoantibodies to become negative again in patients who became positive after receiving immunoglobulin. 2) The incidence of diabetes. (only non-diabetic patient) | — |
Countries
Japan
Contacts
Public ContactJin Kumagai
Chiba University Hospital Department of Diabetes, Metabolism and Endocrinology
Outcome results
None listed